Cargando…
The clinical significance of in-house metagenomic next-generation sequencing for bronchoalveolar lavage fluid diagnostics in patients with lower respiratory tract infections
OBJECTIVE: Metagenomic next-generation sequencing (mNGS) technology has the potential to detect a wide range of pathogenic microorganisms. However, reports on the diagnostic value and clinical significance of different platforms of mNGS for patients with lower respiratory tract infections (LRTIs) re...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801411/ https://www.ncbi.nlm.nih.gov/pubmed/36590589 http://dx.doi.org/10.3389/fcimb.2022.961746 |
_version_ | 1784861492064026624 |
---|---|
author | Li, Shixiao Qin, Jiajia Zhou, Peng Peng, Minfei Qian, Jiao Cai, Yingying Shi, Qingxin Tung, Tao-Hsin Shen, Bo Yu, Sufei |
author_facet | Li, Shixiao Qin, Jiajia Zhou, Peng Peng, Minfei Qian, Jiao Cai, Yingying Shi, Qingxin Tung, Tao-Hsin Shen, Bo Yu, Sufei |
author_sort | Li, Shixiao |
collection | PubMed |
description | OBJECTIVE: Metagenomic next-generation sequencing (mNGS) technology has the potential to detect a wide range of pathogenic microorganisms. However, reports on the diagnostic value and clinical significance of different platforms of mNGS for patients with lower respiratory tract infections (LRTIs) remain scarce. METHODS: A total of 306 patients with suspected LRTIs were enrolled from January 2019 to December 2021. The diagnostic performance of conventional methods and mNGS on bronchoalveolar lavage fluid (BALF) were compared. BALF mNGS was performed using a commercial and an in-house laboratory. The diagnostic value and the clinical implications of mNGS for LRTIs were analyzed for the different platforms. RESULTS: The positive rate of mNGS in the in-house group was higher than that in the commercial group (85.26% vs. 70.67%, p < 0.001). mNGS significantly increased the pathogen detection rate compared with conventional methods [from 70.67% vs. 22.67% (p < 0.001) to 85.26% vs. 30.77% (p < 0.001)]. The pathogens detected using mNGS included bacteria, fungi, viruses, and atypical pathogens. The in-house platform performed well on a wider spectrum of microbial distribution. Furthermore, it showed an advantage in detecting mixed pathogens in immunocompromised patients. Among the mNGS positive cases, 34 (32.0%) cases had their antibiotics adjusted in the commercial group, while 51 (38.3%) cases had a change of treatment in the in-house group. Moreover, the turnaround time of mNGS and the time from mNGS to discharge in the in-house group were significantly shorter than those in the commercial group. CONCLUSION: In-house mNGS had a higher detection rate and can show a wider spectrum of pathogens, with potential benefits for the clinic by shortening the turnaround time and hospitalization, and it may be more suitable for clinical microbiology laboratories. |
format | Online Article Text |
id | pubmed-9801411 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98014112022-12-31 The clinical significance of in-house metagenomic next-generation sequencing for bronchoalveolar lavage fluid diagnostics in patients with lower respiratory tract infections Li, Shixiao Qin, Jiajia Zhou, Peng Peng, Minfei Qian, Jiao Cai, Yingying Shi, Qingxin Tung, Tao-Hsin Shen, Bo Yu, Sufei Front Cell Infect Microbiol Cellular and Infection Microbiology OBJECTIVE: Metagenomic next-generation sequencing (mNGS) technology has the potential to detect a wide range of pathogenic microorganisms. However, reports on the diagnostic value and clinical significance of different platforms of mNGS for patients with lower respiratory tract infections (LRTIs) remain scarce. METHODS: A total of 306 patients with suspected LRTIs were enrolled from January 2019 to December 2021. The diagnostic performance of conventional methods and mNGS on bronchoalveolar lavage fluid (BALF) were compared. BALF mNGS was performed using a commercial and an in-house laboratory. The diagnostic value and the clinical implications of mNGS for LRTIs were analyzed for the different platforms. RESULTS: The positive rate of mNGS in the in-house group was higher than that in the commercial group (85.26% vs. 70.67%, p < 0.001). mNGS significantly increased the pathogen detection rate compared with conventional methods [from 70.67% vs. 22.67% (p < 0.001) to 85.26% vs. 30.77% (p < 0.001)]. The pathogens detected using mNGS included bacteria, fungi, viruses, and atypical pathogens. The in-house platform performed well on a wider spectrum of microbial distribution. Furthermore, it showed an advantage in detecting mixed pathogens in immunocompromised patients. Among the mNGS positive cases, 34 (32.0%) cases had their antibiotics adjusted in the commercial group, while 51 (38.3%) cases had a change of treatment in the in-house group. Moreover, the turnaround time of mNGS and the time from mNGS to discharge in the in-house group were significantly shorter than those in the commercial group. CONCLUSION: In-house mNGS had a higher detection rate and can show a wider spectrum of pathogens, with potential benefits for the clinic by shortening the turnaround time and hospitalization, and it may be more suitable for clinical microbiology laboratories. Frontiers Media S.A. 2022-12-15 /pmc/articles/PMC9801411/ /pubmed/36590589 http://dx.doi.org/10.3389/fcimb.2022.961746 Text en Copyright © 2022 Li, Qin, Zhou, Peng, Qian, Cai, Shi, Tung, Shen and Yu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cellular and Infection Microbiology Li, Shixiao Qin, Jiajia Zhou, Peng Peng, Minfei Qian, Jiao Cai, Yingying Shi, Qingxin Tung, Tao-Hsin Shen, Bo Yu, Sufei The clinical significance of in-house metagenomic next-generation sequencing for bronchoalveolar lavage fluid diagnostics in patients with lower respiratory tract infections |
title | The clinical significance of in-house metagenomic next-generation sequencing for bronchoalveolar lavage fluid diagnostics in patients with lower respiratory tract infections |
title_full | The clinical significance of in-house metagenomic next-generation sequencing for bronchoalveolar lavage fluid diagnostics in patients with lower respiratory tract infections |
title_fullStr | The clinical significance of in-house metagenomic next-generation sequencing for bronchoalveolar lavage fluid diagnostics in patients with lower respiratory tract infections |
title_full_unstemmed | The clinical significance of in-house metagenomic next-generation sequencing for bronchoalveolar lavage fluid diagnostics in patients with lower respiratory tract infections |
title_short | The clinical significance of in-house metagenomic next-generation sequencing for bronchoalveolar lavage fluid diagnostics in patients with lower respiratory tract infections |
title_sort | clinical significance of in-house metagenomic next-generation sequencing for bronchoalveolar lavage fluid diagnostics in patients with lower respiratory tract infections |
topic | Cellular and Infection Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801411/ https://www.ncbi.nlm.nih.gov/pubmed/36590589 http://dx.doi.org/10.3389/fcimb.2022.961746 |
work_keys_str_mv | AT lishixiao theclinicalsignificanceofinhousemetagenomicnextgenerationsequencingforbronchoalveolarlavagefluiddiagnosticsinpatientswithlowerrespiratorytractinfections AT qinjiajia theclinicalsignificanceofinhousemetagenomicnextgenerationsequencingforbronchoalveolarlavagefluiddiagnosticsinpatientswithlowerrespiratorytractinfections AT zhoupeng theclinicalsignificanceofinhousemetagenomicnextgenerationsequencingforbronchoalveolarlavagefluiddiagnosticsinpatientswithlowerrespiratorytractinfections AT pengminfei theclinicalsignificanceofinhousemetagenomicnextgenerationsequencingforbronchoalveolarlavagefluiddiagnosticsinpatientswithlowerrespiratorytractinfections AT qianjiao theclinicalsignificanceofinhousemetagenomicnextgenerationsequencingforbronchoalveolarlavagefluiddiagnosticsinpatientswithlowerrespiratorytractinfections AT caiyingying theclinicalsignificanceofinhousemetagenomicnextgenerationsequencingforbronchoalveolarlavagefluiddiagnosticsinpatientswithlowerrespiratorytractinfections AT shiqingxin theclinicalsignificanceofinhousemetagenomicnextgenerationsequencingforbronchoalveolarlavagefluiddiagnosticsinpatientswithlowerrespiratorytractinfections AT tungtaohsin theclinicalsignificanceofinhousemetagenomicnextgenerationsequencingforbronchoalveolarlavagefluiddiagnosticsinpatientswithlowerrespiratorytractinfections AT shenbo theclinicalsignificanceofinhousemetagenomicnextgenerationsequencingforbronchoalveolarlavagefluiddiagnosticsinpatientswithlowerrespiratorytractinfections AT yusufei theclinicalsignificanceofinhousemetagenomicnextgenerationsequencingforbronchoalveolarlavagefluiddiagnosticsinpatientswithlowerrespiratorytractinfections AT lishixiao clinicalsignificanceofinhousemetagenomicnextgenerationsequencingforbronchoalveolarlavagefluiddiagnosticsinpatientswithlowerrespiratorytractinfections AT qinjiajia clinicalsignificanceofinhousemetagenomicnextgenerationsequencingforbronchoalveolarlavagefluiddiagnosticsinpatientswithlowerrespiratorytractinfections AT zhoupeng clinicalsignificanceofinhousemetagenomicnextgenerationsequencingforbronchoalveolarlavagefluiddiagnosticsinpatientswithlowerrespiratorytractinfections AT pengminfei clinicalsignificanceofinhousemetagenomicnextgenerationsequencingforbronchoalveolarlavagefluiddiagnosticsinpatientswithlowerrespiratorytractinfections AT qianjiao clinicalsignificanceofinhousemetagenomicnextgenerationsequencingforbronchoalveolarlavagefluiddiagnosticsinpatientswithlowerrespiratorytractinfections AT caiyingying clinicalsignificanceofinhousemetagenomicnextgenerationsequencingforbronchoalveolarlavagefluiddiagnosticsinpatientswithlowerrespiratorytractinfections AT shiqingxin clinicalsignificanceofinhousemetagenomicnextgenerationsequencingforbronchoalveolarlavagefluiddiagnosticsinpatientswithlowerrespiratorytractinfections AT tungtaohsin clinicalsignificanceofinhousemetagenomicnextgenerationsequencingforbronchoalveolarlavagefluiddiagnosticsinpatientswithlowerrespiratorytractinfections AT shenbo clinicalsignificanceofinhousemetagenomicnextgenerationsequencingforbronchoalveolarlavagefluiddiagnosticsinpatientswithlowerrespiratorytractinfections AT yusufei clinicalsignificanceofinhousemetagenomicnextgenerationsequencingforbronchoalveolarlavagefluiddiagnosticsinpatientswithlowerrespiratorytractinfections |